Pharmacokinetics of 4'-epi-doxorubicin in Man

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 1983 Jan 1

PMID 6590528

Citations 25

Authors

H Weenen

J Lankelma

P G Penders

J G McVie

W W Ten Bokkel Huinink

M M de Planque

H M Pinedo

Affiliations

Soon will be listed here.

Abstract

The pharmacokinetics of 4'-epi-doxorubicin (4'-epi-adriamycin, 4'-epi-DX) in man can be described by a three-compartment model with a rapid distribution phase and a very long elimination phase. Urine excretion amounts to a total of about 11% of the administered dose during 48 h after drug administration, and less than 1% during the following 48 h. In plasma 4'-epi-doxorubicin is rapidly converted to five metabolites (4'-epi-doxorubicinol, aglycones and glucuronides), the concentration of the aglycones sometimes exceeding that of 4'-epi-DX. In urine only three metabolites were found in addition to the parent drug; they were identified as 4'-epi-doxorubicinol (EOH), 4'-epi-doxorubicin-glucuronide (E-Glu) and 4'-epi-doxorubicinol-glucuronide (EOH-Glu). Comparison of the pharmacokinetics and metabolic profiles of 4'-epi-DX and doxorubicin (DX) in man revealed that 4'-epi-DX eliminates faster than DX.

Citing Articles

Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Ramirez J, Ratain M, Innocenti F Future Oncol. 2010; 6(4):563-85.

PMID: 20373870 PMC: 3102300. DOI: 10.2217/fon.10.17.

Interactions between antiretrovirals and antineoplastic drug therapy.

Antoniou T, Tseng A Clin Pharmacokinet. 2005; 44(2):111-45.

PMID: 15656694 DOI: 10.2165/00003088-200544020-00001.

Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.

Mross K, Hamm K, Hossfeld D Cancer Chemother Pharmacol. 1993; 31(5):369-75.

PMID: 8431970 DOI: 10.1007/BF00686150.

Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.

Camaggi C, Strocchi E, Carisi P, Martoni A, Melotti B, Pannuti F Cancer Chemother Pharmacol. 1993; 32(4):301-9.

PMID: 8324872 DOI: 10.1007/BF00686176.

Clinical pharmacokinetics of epirubicin.

Robert J Clin Pharmacokinet. 1994; 26(6):428-38.

PMID: 8070217 DOI: 10.2165/00003088-199426060-00002.

References

Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, CASAZZA A . Preliminary phase I study of 4'-epi-adriamycin. Cancer Treat Rep. 1979; 63(5):915-8. View

Lankelma J, Penders P, McVie J, Leyva A, de Planque M, Pinedo H . Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography. Eur J Cancer Clin Oncol. 1982; 18(4):363-7. DOI: 10.1016/0277-5379(82)90007-4. View

Tavoloni N, Guarino A, Berk P . Photolytic degradation of adriamycin. J Pharm Pharmacol. 1980; 32(12):860-2. DOI: 10.1111/j.2042-7158.1980.tb13094.x. View

Takanashi S, Bachur N . Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos. 1976; 4(1):79-87. View

CASAZZA A . Experimental evaluation of anthracycline analogs. Cancer Treat Rep. 1979; 63(5):835-44. View